The 2012 Nobel Prize in Physiology and Medicine was awarded to Shinya Yamanaka of Kyoto University in Japan and John Gurdon of the University of Cambridge in England. Dr. Yamanaka and Dr. Gurdon received the award "for the discovery that mature cells can be reprogrammed to become pluripotent," an important step in the widespread commercialization of stem cell therapies.
While many stem cell therapies are still in experimental stages, or too costly for mass adoption, ongoing advances in the space are prevalent. It's becoming widely accepted amongst medical researchers that stem cell therapies will soon be able to treat cancer, diabetes, neurological disorders, muscle damage, Parkinson's, cardiac failure, and many other diseases.
One company with a first-mover advantage in China's stem cell market is Cellular Biomedicine Group ("CBMG"). CBMG has successfully acquired, transferred, commercialized and advanced 30 years of research and human treatment experience in progenitor cells and cancer cell technology. The Company's cellular research and development is the result of collaboration between scientists and doctors from both the U.S. and China.
CBMG announced on Nov. 14, 2012 that it entered into an agreement to merge with EastBridge Investment Group Corp. (OTCQB: EBIG), a financial consulting firm focused on providing professional advice to small, high-growth companies seeking to access the U.S. capital markets. The merger is anticipated to complete in January 2013. The combined entity will operate in two segments, with EastBridge continuing its current operational focus as a division of the parent company.
CBMG scientists currently develop biomedicine based on tissue-derived progenitor (stem) cells, embryonic stem cells (NYSE:ES), cytokine induced killer cells (NYSEMKT:CIK) and cancer-specific dendritic cells. The Company considers these types of cells as viable options for cell-based therapies that can be applied to a variety of medical indications. Ongoing research will determine the most effective applications for each type of cell.
The Company's technologies are founded on scientific innovations in the field of regenerative medicine. CBMG's IP portfolio of cellular biomedicine products target cancer, osteoarthritis, tissue damage as a result of stroke, spinal muscular atrophy, various inflammatory diseases, joint repair, metabolic diseases and ophthalmology diseases.
Investors have a lot of upside with CBMG. It has the right management and scientific team in place to move its robust product pipeline through to commercialization. As an added bonus, once the merger with EBIG is complete in January, the Company will have additional high-margin revenue generation from EBIG's core financial consulting business. This added cash flow will further support the Company's product development efforts.
To learn more about this exciting opportunity with China's stem cell leader, view CBMG's recent presentation from our December virtual conference or contact a specialist today at 1-407-644-4256, ext. 0.
Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.